Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Ferdinand, Ploner"'
Autor:
Angelika Bezan, Florian Posch, Ferdinand Ploner, Thomas Bauernhofer, Martin Pichler, Joanna Szkandera, Georg C Hutterer, Karl Pummer, Thomas Gary, Hellmut Samonigg, Joerg Beyer, Thomas Winder, Thomas Hermanns, Christian D Fankhauser, Armin Gerger, Michael Stotz
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176283 (2017)
BACKGROUND:Patients with testicular germ cell tumors (TGCT) have an increased risk for venous thromboembolism (VTE). We identified risk factors for VTE in this patient cohort and developed a clinical risk model. METHODS:In this retrospective cohort s
Externí odkaz:
https://doaj.org/article/04305b8cf2fc405a86ba08b19f54474e
Autor:
Joanna Szkandera, Armin Gerger, Bernadette Liegl-Atzwanger, Michael Stotz, Hellmut Samonigg, Ferdinand Ploner, Tatjana Stojakovic, Andreas Leithner, Martin Pichler
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107297 (2014)
Anemia refers to low hemoglobin (Hb) levels, represents a common symptom and complication in cancer patients and was reported to negatively influence survival in patients with various malignancies. In the present study, we aimed to explore the progno
Externí odkaz:
https://doaj.org/article/b9bbfdf1e2e44289b458d5626d607dc8
Autor:
Ferdinand Ploner
Publikováno v:
memo - Magazine of European Medical Oncology. 7:237-241
At the American Society of Clinical Oncology (ASCO) meeting 2014, the most striking abstracts on lung cancer treatment addressed—as expected—aspects of targeted therapy. The most probable practice changing data came from the presentation of the P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33fb62e684f4b74aef943fa3b79654c7
https://doi.org/10.1007/s12254-014-0180-6
https://doi.org/10.1007/s12254-014-0180-6
Autor:
Katharina Eberhard, Bernadette Liegl-Atzwanger, Hellmut Samonigg, Ferdinand Ploner, Michael Stotz, Armin Gerger, Andreas Leithner, Joanna Szkandera, Gudrun Absenger, Martin Pichler, Tatjana Stojakovic
Publikováno v:
Journal of Surgical Oncology. 109:139-144
Background and Objectives Accumulating evidence indicates an important pathophysiological role of fibrinogen on tumor cell progression and metastases in different types of cancer. The aim of the present study was to evaluate the prognostic relevance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce4811d7a33d46f430d8be6a874fce14
https://doi.org/10.1002/jso.23458
https://doi.org/10.1002/jso.23458
Autor:
Hellmut Samonigg, Werner Maurer-Ertl, Gudrun Absenger, Andreas Leithner, Joanna Szkandera, Tatjana Stojakovic, Martin Pichler, Armin Gerger, Michael Stotz, Ferdinand Ploner, Bernadette Liegl-Atzwanger
Publikováno v:
British Journal of Cancer
Background: The concept of the involvement of systemic inflammation in cancer progression and metastases has gained attraction within the past decade. C-reactive protein (CRP), a non-specific blood-based marker of the systemic inflammatory response,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f0b7386f676a8ea7c7b97b82c9523b
https://doi.org/10.1038/bjc.2013.595
https://doi.org/10.1038/bjc.2013.595
Autor:
Georg Hutarew, William Sterlacci, Patricia Grabher, Ulrike Setinek, Gerald Webersinke, Klaus Kirchbacher, Michael Vesely, Helmut Popper, Wolfgang Hilbe, Elvira Stacher, Rainer Kolb, Maximilian Hochmair, Wolfgang Hulla, Hans Maier, Tamara Hernler, Leonhard Müllauer, Ferdinand Ploner, Ulrike Gruber-Moesenbacher, Robert Pirker
Publikováno v:
memo - Magazine of European Medical Oncology. 6:83-91
The introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for non-small cell lung cancer (NSCLC) with activating mutations of the EGFR has opened a new area of lung cancer treatment strategies and led to an enthusia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ea91d21581483b360959cef70ff6cba
https://doi.org/10.1007/s12254-013-0087-7
https://doi.org/10.1007/s12254-013-0087-7
Autor:
B. Mlineritsch, Michael Gnant, Werner Kwasny, Ferdinand Ploner, Christian F. Singer, Martin Moik, Michael Seifert, Georg Pfeiler, P. Sandbichler, Richard Greil, Peter Dubsky, Friedrich Hofbauer, U Selim, Hellmut Samonigg, Florian Fitzal, Marija Balic, Christian Fesl, Raimund Jakesz, Herbert Stöger, Günther G. Steger, K Renner
Publikováno v:
British Journal of Cancer
Background: There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship between BMI and the efficacy of tamoxifen is conflicting. We investigated the impact of BMI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0065f0a697c9a31c5628e7695f5e1a
https://doi.org/10.1038/bjc.2013.114
https://doi.org/10.1038/bjc.2013.114
Autor:
Gudrun Absenger, Ferdinand Ploner
Publikováno v:
memo - Magazine of European Medical Oncology. 6:9-13
Malignancies originating from thymic epithelial tissue are rare and treatment approach depends on the individual situation. There are no randomized trials that provide evidence of therapy for patients with thymoma and thymic carcinoma. Treatment incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e72895e6823e8244fb808f891f3255f
https://doi.org/10.1007/s12254-013-0069-9
https://doi.org/10.1007/s12254-013-0069-9
Autor:
A. K. Kasparek, Hellmut Samonigg, Elisabeth Andritsch, Hans Andritsch, H. Stöger, R. Schaberl-Moser, Thomas Bauernhofer, Ferdinand Ploner
Publikováno v:
Palliative and Supportive Care. 11:215-221
Change affects all areas of healthcare organizations and none more so than each aspect of the oncology ward, beginning with the patient's room. It is there that the issues faced by the major players in healing environments – administrator, caregive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b9aa7d2ce866721b96a14e7d95572b
https://doi.org/10.1017/s1478951512000077
https://doi.org/10.1017/s1478951512000077
Autor:
Michael Studnicka, Helmut Popper, Robert Pirker, Fritz Wrba, Wolfgang Hulla, Wolfgang Hilbe, Ulrike Gruber-Mösenbacher, Ferdinand Ploner, Andrea Mohn-Staudner
Publikováno v:
memo - Magazine of European Medical Oncology. 4:248-253
Patients with stage IIIB and IV non-small-cell lung carcinoma (NSCLC) harbouring activating mutations of the epidermal growth factor receptor (EGFR) gene should be treated first-line with gefitinib or erlotinib, EGFR tyrosine kinase inhibitors (TKI).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e672016f2c59fcbd446fcb1da8eadcb
https://doi.org/10.1007/s12254-011-0319-7
https://doi.org/10.1007/s12254-011-0319-7